Phase I clinical trial of exherin (ADH-1) in patients with advanced solid tumors

Current Clinical Pharmacology

Volumn 8, Issue 1, 2013, Pages 81-88

  Yarom, Nirit ^a   Stewart, David ^b   Malik, Rajesh ^c   Wells, Julie ^a   Avruch, Leonard ^a   Jonker, Derek J ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c AGENNIX INC   (United States)

Author keywords

Adh 1; Dynamic contrast enhanced magnetic resonance imaging (dce mri); E cadherin; N cadherin; Phase i; Solid tumors

Indexed keywords

ADH 1; ANTINEOPLASTIC AGENT; EXHERIN; NERVE CELL ADHESION MOLECULE; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER SIZE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTRAST ENHANCEMENT; COUGHING; DIARRHEA; DISEASE CONTROL; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DYSGEUSIA; DYSPEPSIA; DYSPNEA; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FLUSHING; HEART MUSCLE ISCHEMIA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE OBSTRUCTION; KIDNEY CARCINOMA; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; NOCTURIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SIDE EFFECT; STEADY STATE; THORAX PAIN; TREATMENT RESPONSE; TUMOR BLOOD FLOW; UPPER ABDOMINAL PAIN; URINE INCONTINENCE; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 84873134086     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711308010011     Document Type: Article

References (13)

1. Geiger B, Ayalon O. Cadherins. Annu Rev Cell Biol 1992; 8: 307-32.
2. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-9.
3. Schmidmaier R, Baumann P. Anti adhesion evolves to a promising therapeutic concept in oncology. Curr Med Chem 2008; 15: 978-90.
4. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004; 164: 193-203.
5. Lepekhin EJX, Michaud S, Tonary A, Yu W, Symonds JM, Blaschuk OW. Adherex Technologies Inc, editor. Early and longterm effects of exherin on tumor vasculature. ASCO 2003; Annual Meeting: American Society of Clinical Oncology 2003.
6. Mariotti A, Perotti A, Sessa C, Ruegg C. N-cadherin as a therapeutic target in cancer. Expert OpinInvestig Drugs 2007; 16: 451-65.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981: 47: 207-214
8. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J MagnReson Imaging 1999; 10: 254-259.
9. Evelhoch JL. Tracer measurements of blood flow. In Gillies R, editor. NMR in physiology and biomedicine. SanDiego: Academic press; 1994; P209-220.
10. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92: 1599-610.
11. Zweifel M, Padhani AR. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging 2010; 37(Suppl 1): S164-82.
12. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010; 11: 1172-83.
13. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-95.